About: Molecular characterization of a panel of murine monoclonal antibodies specific for the SARS-coronavirus

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Molecular characterization of a panel of murine monoclonal antibodies specific for the SARS-coronavirus Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Molecular characterization of a panel of murine monoclonal antibodies specific for the SARS-coronavirus
Creator	Andonov, Anton Berry, Jody Andonova, Maya Plummer, Frank Drebot, Mike Johnstone, Darrell Yuan, Y Gubbins, Michael
topic	covid:69403975272536434ad77f177871ffa4c828873e#this
Source	Elsevier; Medline; PMC
abstract	Abstract The availability of monoclonal antibodies (mAbs) specific for the SARS-coronavirus (SARS-CoV) is important for the development of both diagnostic tools and treatment of infection. A molecular characterization of nine monoclonal antibodies raised in immune mice, using highly purified, inactivated SARS-CoV as the inoculating antigen, is presented in this report. These antibodies are specific for numerous viral protein targets, and six of them are able to effectively neutralize SARS-CoV in vitro, including one with a neutralizing titre of 0.075nM. A phylogenetic analysis of the heavy and light chain sequences reveals that the mAbs share considerable homology. The majority of the heavy chains belong to a single Ig germline V-gene family, while considerably more sequence variation is evident in the light chain sequences. These analyses demonstrate that neutralization ability can be correlated with specific murine VH-gene alleles. For instance, one evident trend is high sequence conservation in the VH chains of the neutralizing mAbs, particularly in CDR-1 and CDR-2. The results suggest that optimization of murine mAbs for neutralization of SARS-CoV infection will likely be possible, and will aid in the development of diagnostic tools and passive treatments for SARS-CoV infection.
has issue date	2005-01-31(xsd:dateTime)
bibo:doi	10.1016/j.molimm.2004.06.032
bibo:pmid	15488951
has license	els-covid
sha1sum (hex)	69403975272536434ad77f177871ffa4c828873e
schema:url	https://doi.org/10.1016/j.molimm.2004.06.032
resource representing a document's title	Molecular characterization of a panel of murine monoclonal antibodies specific for the SARS-coronavirus
has PubMed Central identifier	PMC7112650
has PubMed identifier	15488951
schema:publication	Molecular Immunology
resource representing a document's body	covid:69403975272536434ad77f177871ffa4c828873e#body_text
is http://vocab.deri.ie/void#inDataset of	https://covidontheweb.inria.fr:4443/about/id/http/ns.inria.fr/covid19/69403975272536434ad77f177871ffa4c828873e
is schema:about of	named entity 'PANEL' named entity 'phylogenetic analysis' named entity 'homology' named entity 'alleles' named entity 'panel' named entity 'CORONAVIRUS' named entity 'CHARACTERIZATION' named entity 'IMPORTANT' named entity 'CHARACTERIZATION' named entity 'AVAILABILITY OF' named entity 'SARS-COV' named entity 'TREATMENT' named entity '0.075' named entity 'REVEALS' named entity 'HIGH' named entity 'CHAINS' named entity 'PROTEIN ' named entity 'HOMOLOGY' named entity 'TARGETS' named entity 'CONSIDERABLE' named entity 'MICE' named entity 'V-GENE' named entity 'TREND' named entity 'NUMEROUS' named entity 'THESE' named entity 'SEQUENCES' named entity 'SARS' named entity 'HEAVY' named entity 'ABILITY' named entity 'ANTIGEN' named entity 'PURIFIED' named entity 'SEQUENCE' named entity 'SHARE' named entity 'GENE FAMILY' named entity 'MOLECULAR' named entity 'CORONAVIRUS' named entity 'MONOCLONAL ANTIBODIES' named entity 'SUGGEST' named entity 'OPTIMIZATION' named entity 'INSTANCE' named entity 'MAJORITY' named entity 'ANTIBODIES SPECIFIC' named entity 'MURINE' named entity 'SPECIFIC' named entity 'INCLUDING' named entity 'RAISED' named entity 'DEVELOPMENT' named entity 'SARS' named entity 'INACTIVATED' named entity 'H -' named entity 'DIAGNOSTIC' named entity 'SINGLE' named entity 'HIGHLY' named entity 'TREATMENTS' named entity 'CONSERVATION' named entity 'ANTIBODIES' named entity 'ALLELES' named entity 'INFECTION' named entity 'SEQUENCE VARIATION' named entity 'PASSIVE' named entity 'SARS-COV INFECTION' named entity 'PRESENTED' named entity 'TOOLS' named entity 'IN VITRO' named entity 'MONOCLONAL ANTIBODIES' named entity 'GENE' named entity 'USING' named entity 'VIRAL PROTEIN' named entity 'REPORT' named entity 'AID' named entity 'CDR' named entity 'TITRE'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software